• Regentis Biomaterials attended the 8th ICRS Summit in Porto, Portugal, held Oct. 8-10, 2026.
• Booth discussions with surgeons centered on GelrinC, a CE Marked, off-the-shelf hydrogel implant for knee cartilage regeneration.
• Company highlighted Phase II data showing about 100% greater KOOS improvement versus historical microfracture controls at two years.
• Management pointed to European Centers of Excellence to support surgeon training, with European sites also participating in a U.S. FDA pivotal trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610120900ACCESSWRNAPR_____1235544) on October 12, 2026, and is solely responsible for the information contained therein.